Enabling access to molecular monitoring for chronic myeloid leukemia patients is cost effective in China.
<h4>Objective</h4>To determine the cost effectiveness of molecular monitoring in patients with chronic myeloid leukemia in the chronic phase (CML-CP) compared to no molecular monitoring from a Chinese payer perspective.<h4>Methods</h4>Analyses were conducted using a semi-Mark...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0259076 |